The Sept. 12 series A funding round helped launch Pretzel Therapeutics, which aims to develop novel therapies for conditions affected by dysfunctional mitochondria, including Alzheimer’s and Parkinson’s diseases.
“The expertise we have assembled and the platform technologies we have created will allow new inroads into treating both rare genetic diseases as well as common diseases of aging,” said Jay Parrish, PhD, board chair and CEO of Pretzel, in a Sept. 12 company news release.
Pretzel’s scientific advisory board consists of two Nobel laureates. Arch Venture Partners and Mubadala Capital led the investment round.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
